Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice

Abstract

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have beneficial effects on cardiovascular disease in addition to their glucose-lowering effects. In this study, the effects of these drugs, when used individually or in combination, on cardiovascular atherosclerotic lesion development were compared in diabetic ApoE-deficient (ApoE KO) hyperlipidemic mice.

Methods ApoE-KO mice were treated with streptozotocin and nicotinamide, generating a type 2 diabetes model. The mice were randomly divided into four groups: vehicle-treated (untreated), liraglutide (LIRA), ipragliflozin (IPRA), and combination therapy (combo). These mice, as well as non-diabetic controls, were fed a high-fat diet. After 8 weeks of drug administration, the heart and aorta were removed and analyzed.

Results Atherosclerotic lesions evaluated by oil red O (ORO) staining were significantly larger in the untreated group (13.4±0.8% of the total aortic area) than in the non-diabetic controls (4.4±0.5%, p<0.01), while being reduced in the combo group (6.0±1.0%, p<0.01) as compared with the untreated group. The ORO stain-positive area in the LIRA and IPRA groups tended to be reduced but their differences were not statistically significant. Transcript levels of Mcp1 and Sirt1 were significantly reduced and increased, respectively, in the combo compared with the untreated group, while no significant changes were observed in the monotherapy groups.

Conclusions The data suggest that combination therapy with liraglutide and ipragliflozin may be an efficient regimen for preventing the development of atherosclerosis in diabetic mice deficient in ApoE.

Keywords

atherosclerosis - SGLT2i - GLP-1RA

Publikationsverlauf

Eingereicht: 29. Dezember 2023
Eingereicht: 09. April 2024

Angenommen: 16. April 2024

Accepted Manuscript online:
16. April 2024

Artikel online veröffentlicht:
29. Mai 2024

• References

• 1 Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: Contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011; 18: 629-639
• 2 Tang H, kimmel SE, Smith SM. et al. Comparable cardiorenal benefits of SGLT2 inhibitors and GLP-1RAs in Asian and white populations: An updated meta-analysis of results from randomized outcome trials. Diabetes Care 2022; 45: 1007-1012
• 3 Nakatsu Y, Kokubo H, Bumdelger B. et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci 2017; 18: 1704
• 4 Vinué Á, Navarro J, Herrero-Cervera A. et al. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia 2017; 60: 1801-1812
• 5 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
• 6 Packer M, Anker SD, Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413-1424
• 7 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451-1461
• 8 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357
• 9 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008
• 10 Solomon SD, de Boer RA, DeMets D. et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial. Eur J Heart Fail 2021; 23: 1217-1225
• 11 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
• 12 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
• 13 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
• 14 Hernandez AF, Green JB, Janmohamed S. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial. Lancet 2018; 392: 1519-1529
• 15 American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2022. Diabetes Care 2022; 45: S144-S174
• 16 Rodbard HW, Rosenstock J, Canani LH. et al. Oral Semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care 2019; 42: 2272-2281
• 17 Terasaki M, Hiromura M, Mori Y. et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS One 2015; 10: e0143396
• 18 Leng W, Ouyang X, Lei X. et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE^-/- mice. Mediators Inflamm 2016; 2016: 6305735
• 19 Han JH, Oh TJ, Lee G. et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE ^-/- mice fed a western diet. Diabetologia 2017; 60: 364-376
• 20 Taberner-Cortés A, Vinué Á, Herrero-Cervera A. et al. Dapagliflozin does not modulate atherosclerosis in mice with insulin resistance. Int J Mol Sci 2020; 21: 9216
• 21 Tashiro Y, Sato K, Watanabe T. et al. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 2014; 54: 19-26
• 22 Jojima T, Uchida K, Akimoto K. et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis 2017; 261: 44-51
• 23 Koshibu M, Mori Y, Saito T. et al. Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms. Am J Physiol Endocrinol Metab 2019; 316: E895-E907
• 24 Sanada J, Obata A, Obata Y. et al. Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: The earlier, the better. Sci Rep 2021; 11: 1425
• 25 Koike M, Saito H, Kohno G. et al. Effects of GLP-1RA and SGLT2i, alone or in combination, on mouse models of type 2 diabetes representing different disease stages. Int J Mol Sci 2021; 22: 11463
• 26 Kusunose K, Imai T, Tanaka A. et al Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A sub-analysis of the PROTECT trial. J Cardiol 2024; 18: S0914-S5087 (24) 00020-0
• 27 Rais N, Ved A, Ahmad R. et al. Model of streptozotocin-nicotinamide induced type 2 diabetes: A comparative review. Curr Diabetes Rev 2022; 18: e171121198001
• 28 Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48: 452-428
• 29 Bisgaard LS, Bosteen MH, Fink LN. et al. Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-/- mice. PLoS One 2016; 11: e0168396
• 30 Inoue S, Egashira K, Ni W. et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002; 106: 2700-2706
• 31 Miranda MX, van Tits LJ, Lohmann C. et al. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J 2015; 36: 51-59
• 32 Yun JM, Chien A, Jialal I. et al. Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: Mechanistic insights. J Nutr Biochem 2012; 23: 699-705
• 33 Yang X, Wei J, He Y. et al. SIRT1 inhibition promotes atherosclerosis through impaired autophagy. Oncotarget 2017; 8: 51447-51461
• 34 Zhang Y, Wang S, Chen X. et al. Liraglutide prevents high glucose induced HUVECs dysfunction via inhibition of PINK1/Parkin-dependent mitophagy. Mol Cell Endocrinol 2022; 545: 111560
• 35 Packer M. Cardioprotective Effects of Sirtuin-1 and its downstream effectors: Potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors. Circ Heart Fail 2020; 13: e007197
• 36 Watanabe K, Yamaguchi S, Kosakai Y. et al. Efficacy and safety of switching from sitagliptin to ipragliflozin in obese Japanese patients with type 2 diabetes mellitus: A single-arm multicenter interventional study. Clin Drug Investig 2023; 43: 927-937
• 37 Lam CSP, Ramasundarahettige C, Branch KRH. et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: Exploratory analysis of the AMPLITUDE-O Trial. Circulation 2022; 145: 565-574